Interstitial lung disease in systemic sclerosis: current and future treatment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interstitial lung disease in systemic sclerosis: current and future treatment
Authors
Keywords
Systemic sclerosis, Scleroderma, Interstitial lung disease, Fibrosis, Treatment
Journal
RHEUMATOLOGY INTERNATIONAL
Volume 37, Issue 6, Pages 853-863
Publisher
Springer Nature
Online
2017-01-07
DOI
10.1007/s00296-016-3636-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
- (2016) Dinesh Khanna et al. LANCET
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
- (2016) Donald P Tashkin et al. Lancet Respiratory Medicine
- Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
- (2015) Lisa M. Rice et al. JOURNAL OF CLINICAL INVESTIGATION
- Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders
- (2015) Michele Iudici et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review
- (2015) Mohammed A. Omair et al. PLoS One
- Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
- (2014) Suzana Jordan et al. ANNALS OF THE RHEUMATIC DISEASES
- Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease
- (2014) Tiffany A. Winstone et al. CHEST
- Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series
- (2014) Neslihan Yilmaz et al. International Journal of Rheumatic Diseases
- Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis
- (2014) Jacob M. van Laar et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels
- (2014) Serena Vettori et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Treatment of systemic sclerosis with tocilizumab
- (2014) M. Fernandes das Neves et al. RHEUMATOLOGY
- Mortality and survival in systemic sclerosis: Systematic review and meta-analysis
- (2014) Manuel Rubio-Rivas et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
- (2014) Paolo Fraticelli et al. ARTHRITIS RESEARCH & THERAPY
- Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand
- (2014) Mohan S. Maddur et al. Nature Communications
- Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
- (2013) A. De Lauretis et al. JOURNAL OF RHEUMATOLOGY
- Autologous HSCT for systemic sclerosis
- (2013) Jacob M van Laar et al. LANCET
- Mycophenolate Versus Cyclophosphamide for Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: A 2-Year Case Control Study
- (2013) Stylianos T. Panopoulos et al. LUNG
- Survival after lung transplantation in systemic sclerosis. A systematic review
- (2013) Irfan Y. Khan et al. RESPIRATORY MEDICINE
- Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
- (2012) Muriel Elhai et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
- (2012) Korsa Khan et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis
- (2012) Patrizia Fuschiotti et al. ARTHRITIS AND RHEUMATISM
- Racial differences between blacks and whites with systemic sclerosis
- (2012) Richard M. Silver et al. CURRENT OPINION IN RHEUMATOLOGY
- Chitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF- 1 Signaling
- (2012) C. G. Lee et al. JOURNAL OF IMMUNOLOGY
- Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
- (2012) O. A. Moore et al. RHEUMATOLOGY
- Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
- (2011) R. F. Spiera et al. ANNALS OF THE RHEUMATIC DISEASES
- A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease
- (2011) Dinesh Khanna et al. ARTHRITIS AND RHEUMATISM
- Integrating mechanisms of pulmonary fibrosis
- (2011) Thomas A. Wynn JOURNAL OF EXPERIMENTAL MEDICINE
- Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial
- (2011) Richard K Burt et al. LANCET
- Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis
- (2011) Hadi Poormoghim et al. RHEUMATOLOGY INTERNATIONAL
- Reply
- (2010) James R. Seibold et al. ARTHRITIS AND RHEUMATISM
- Cigarette smoking in patients with systemic sclerosis
- (2010) Marie Hudson et al. ARTHRITIS AND RHEUMATISM
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
- (2010) Y. Shima et al. RHEUMATOLOGY
- Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab
- (2010) Wan-Hee Yoo RHEUMATOLOGY INTERNATIONAL
- B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
- (2010) Silvia Bosello et al. ARTHRITIS RESEARCH & THERAPY
- Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFβ Expression
- (2009) Timothy R. D. J. Radstake et al. PLoS One
- The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications
- (2009) Sophie P. Toya et al. RHEUMATOLOGY INTERNATIONAL
- Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials
- (2009) Karen Au et al. Current Rheumatology Reports
- CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma
- (2008) Ayumi Yoshizaki et al. AMERICAN JOURNAL OF PATHOLOGY
- Interstitial Lung Disease in Systemic Sclerosis
- (2008) Nicole S. L. Goh et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Pulmonary function tests
- (2008) J. Behr et al. RHEUMATOLOGY
- Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
- (2008) Carlotta Nannini et al. ARTHRITIS RESEARCH & THERAPY
- Role of Interleukin-6 in Bleomycin-Induced Lung Inflammatory Changes in Mice
- (2007) Fumitake Saito et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now